BRPI0816823A8 - Formulação contendo composto inibidor de quinase dependente de ciclina e método de tratamento de tumores que a utiliza - Google Patents

Formulação contendo composto inibidor de quinase dependente de ciclina e método de tratamento de tumores que a utiliza

Info

Publication number
BRPI0816823A8
BRPI0816823A8 BRPI0816823A BRPI0816823A BRPI0816823A8 BR PI0816823 A8 BRPI0816823 A8 BR PI0816823A8 BR PI0816823 A BRPI0816823 A BR PI0816823A BR PI0816823 A BRPI0816823 A BR PI0816823A BR PI0816823 A8 BRPI0816823 A8 BR PI0816823A8
Authority
BR
Brazil
Prior art keywords
dependent kinase
formulation containing
treatment method
kinase inhibitor
inhibitor compound
Prior art date
Application number
BRPI0816823A
Other languages
English (en)
Inventor
Antochshuk Valentyn
Bannerji Rajat
Dabbara Anita
Kirschmeier Paul
A Parry David
Shameem Mohammed
Statkevich Paul
Yao Siu-Long
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0816823A2 publication Critical patent/BRPI0816823A2/pt
Publication of BRPI0816823A8 publication Critical patent/BRPI0816823A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÃO CONTENDO COMPOSTO INIBIDOR DE QUINASE DEPENDENTE DE CICLINA E MÉTODO DE TRATAMENTO DE TUMORES QUE A UTILIZA. A presente invenção refere-se a uma nova formulação contendo um derivado de pirazol 3-amino-4-substituído que possui propriedades de inibição de quinase dependente de ciclina, e um método de tratamento de tumores usando a nova formulação.
BRPI0816823A 2007-09-17 2008-09-16 Formulação contendo composto inibidor de quinase dependente de ciclina e método de tratamento de tumores que a utiliza BRPI0816823A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99418507P 2007-09-17 2007-09-17
US99946907P 2007-10-17 2007-10-17
US5378408P 2008-05-16 2008-05-16
PCT/US2008/010778 WO2009038701A2 (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same

Publications (2)

Publication Number Publication Date
BRPI0816823A2 BRPI0816823A2 (pt) 2015-03-10
BRPI0816823A8 true BRPI0816823A8 (pt) 2016-02-10

Family

ID=40020243

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816823A BRPI0816823A8 (pt) 2007-09-17 2008-09-16 Formulação contendo composto inibidor de quinase dependente de ciclina e método de tratamento de tumores que a utiliza

Country Status (12)

Country Link
EP (1) EP2200584A2 (pt)
JP (1) JP2010539173A (pt)
KR (1) KR20100072253A (pt)
CN (1) CN101854915A (pt)
AU (1) AU2008301925A1 (pt)
BR (1) BRPI0816823A8 (pt)
CA (1) CA2699761A1 (pt)
CO (1) CO6270205A2 (pt)
MX (1) MX2010002927A (pt)
NZ (1) NZ584037A (pt)
SG (1) SG184760A1 (pt)
WO (1) WO2009038701A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541587A (ja) * 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
JO3190B1 (ar) * 2011-10-19 2018-03-08 Otsuka Pharma Co Ltd محلول للتناول عن طريق الفم
US9827309B2 (en) 2013-08-20 2017-11-28 Merck Sharp & Dohme Corp. Treating cancer with a combination of a PD-1 antagonist and dinaciclib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
CA2699761A1 (en) 2009-03-26
WO2009038701A2 (en) 2009-03-26
JP2010539173A (ja) 2010-12-16
NZ584037A (en) 2012-08-31
EP2200584A2 (en) 2010-06-30
CN101854915A (zh) 2010-10-06
MX2010002927A (es) 2010-06-01
CO6270205A2 (es) 2011-04-20
SG184760A1 (en) 2012-10-30
WO2009038701A3 (en) 2009-09-11
BRPI0816823A2 (pt) 2015-03-10
KR20100072253A (ko) 2010-06-30
AU2008301925A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
HK1222124A1 (zh) 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
NO20081454L (no) Met-kinaseinhibitorer
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
BRPI0514017A (pt) indazóis úteis no tratamento de doenças cardiovasculares
HK1143190A1 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
NO20081952L (no) Substituerte pyrazolforbindelser
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
NO20091864L (no) Forbindelser for inhibering av mitotisk progresjon
EA201300080A1 (ru) Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
EA201170832A1 (ru) Пуриновые соединения
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
BRPI0911161B8 (pt) derivados de piridazinona e seu processo de preparação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES. PAGAR RESTAURACAO.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.